<DOC>
	<DOCNO>NCT02295748</DOCNO>
	<brief_summary>This open label , long-term extension study approximately 24 male DMD subject consist child ( age 4-12 , inclusive ) adolescent ( age 13-16 , inclusive ) participate MP-104-CL-005 PK study .</brief_summary>
	<brief_title>An Open-Label , Long-Term Extension Study Evaluate Safety Tolerability Deflazacort</brief_title>
	<detailed_description>This open label , long-term extension study approximately 24 male DMD subject consist child ( age 4-12 , inclusive ) adolescent ( age 13-16 , inclusive ) participate MP-104-CL-005 PK study . Subjects may receive 8 ( +2 day ) dose deflazacort MP-104-CL-005 PK study , point treatment continue dose frequency time deflazacort become commercially available study terminate . Concomitant corticosteroid therapy prohibit study subject take deflazacort . Subjects give medication take home once-daily , morning dose follow 8 hour PK sample Day 8 ( +2 day ) MP-104-CL-005 PK study . Subjects begin dose home day follow Day 8 ( +2 day ) MP-104-CL-005 PK study . Safety monitor throughout study repeat clinical laboratory evaluation every 3 month first year , every 3 6 month , depend subject ' disease status . Subjects contact via telephone study visit determine adverse event ( AE ) occur since last study visit . Subjects terminate study early contact Principal Investigator ( PI ) deem necessary . Treatment continue maximum three year time deflazacort become commercially available study terminate .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<mesh_term>Deflazacort</mesh_term>
	<criteria>Subject capable understanding comply protocol requirement . Subject , applicable , subject 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . If age 7 , subject sign date write , informed assent form ( IAF ) require privacy authorization prior initiation study procedure . Subjects age 7 time study entry turn age 7 sign date write informed assent form ( IAF ) visit follow 7th birthday , require site 's IRB . Subject participate receive least one dose study medication MP104CL005 protocol . The subject must confirm diagnosis Duchenne Muscular Dystrophy define : 1. onset weakness 5 year age ; 2. proximal muscle weakness ; 3. increase serum creatine kinase 10 time upper limit normal ( ULN ) ; 4. muscle biopsy dystrophin analyse consistent DMD DNA mutation analysis PCR Southern blot technique detect gene deletion . The subject weigh least 13 kg body mass index ( BMI ) â‰¤ 40 kg/m2 . Willingness ability comply schedule visit , oral drug administration , study procedure include blood sample draw safety lab . Up date childhood vaccination , include varicella vaccine ( chicken pox ) . Baseline health judge stable base medical history , physical examination , laboratory profile , vital sign , ECGs screening , deem Investigator . Continuous non smoker use nicotine containing product least 3 month prior first dose . The subject able take tablet . The subject receive investigational compound and/or participate another clinical study within 90 day prior study treatment exception MP104CL005 , observational cohort study noninterventional study . The subject immediate family member , study site employee , dependent relationship study site employee involve conduct study ( e.g . spouse , parent , child , sibling ) may consent duress . Any significant finding Columbia suicide severity rating scale ( C SSRS ) subject ( age 1216 , inclusive ) , opinion PI , warrant exclusion study . The subject , judgment , clinically significant abnormal clinical chemistry laboratory parameter may affect safety Day 0 . The subject , judgment Investigator , history current medical condition could affect safety include , limited : 1 . Major renal hepatic impairment 2 . Immunosuppression contraindication corticosteroid treatment 3 . History chronic systemic fungal viral infection 4 . Diabetes mellitus 5 . Idiopathic hypocalcuria 6 . Symptomatic cardiomyopathy Day 0 The subject history hypersensitivity allergic reaction steroid formulation include , limited lactose , sucrose , etc . Inability take tablet assess site investigator . Subject mentally legally incapacitated significant emotional problem time screen visit expect conduct study . History illness , opinion PI , might confound result study pose additional risk subject participation study . Positive urine drug alcohol result Day 0 . Hemoglobin level lower limit normal Day 0 .</criteria>
	<gender>Male</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>